Related Experiment Video
Updated: Aug 17, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early
Antonio Dal Canton1, Amore Amore, Giancarlo Barbano
1Unit of Nephrology, Dialysis and Transplantation, IRCCS Policlinico San Matteo and University of Pavia, Pavia. dalcanton@mbox.medit.it
Angiotensin converting-enzyme inhibition (ACEI) is a widely accepted treatment during established renal diseases and beneficial effects have also been reported in IgA nephropathy (IgAN). Immunosuppression with myco-phenolate mofetil (MMF) has recently been introduced in the treatment of immune-mediated renal diseases showing promising results. Preliminary clinical reports are also suggestive that MMF is effective in severe forms of IgAN. We propose a randomised prospective trial aimed to compare long-term renal survival of early IgAN in the course of ACEI therapy with or without MMF immunosuppression.
Angiotensin converting-enzyme inhibition (ACEI) is a widely accepted treatment during established renal diseases and beneficial effects have also been reported in IgA nephropathy (IgAN). Immunosuppression with myco-phenolate mofetil (MMF) has recently been introduced in the treatment of immune-mediated renal diseases showing promising results. Preliminary clinical reports are also suggestive that MMF is effective in severe forms of IgAN. We propose a randomised prospective trial aimed to compare long-term renal survival of early IgAN in the course of ACEI therapy with or without MMF immunosuppression.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant I: Introduction
